Anacor Pharmaceuticals, a biopharmaceutical company, has announced positive results from a Phase I clinical trial of AN2718, an investigational topical anti-fungal product candidate for the potential treatment of
John Brown is a PhD pharmacologist who has considerable management experience in the healthcare sector, most recently as chief executive officer of Acambis plc until 2004. Since that
Diamyd Medical, a biopharmaceutical company, has announced that the Swedish Medical Products Agency has approved a study with the Diamyd diabetes vaccine in children with high risk to
Cordex Pharma, a developer of cardiovascular medicines, has filed a formulation patent covering its lead product, ATPace. ATPace is a stable liquid formulation of adenosine triposphate (ATP) for
Anika Therapeutics, a developer and marketer of therapeutic products for tissue protection, healing and repair, has reported net income of $1.09m or $0.10 per diluted share for the
Bristol-Myers Squibb Company has signed a global collaboration agreement with Japan-based manufacturing company Nissan Chemical Industries, and Teijin Pharma for the development and commercialization of NTC-801, a selective
ThromboGenics, a biotechnology company, has completed patient enrollment for a Phase II trial of microplasmin intravitreal injection for the treatment of diabetic macular edema. According to the company,
Proteon Therapeutics, a biopharmaceutical company, has successfully completed a $38m series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund.
Financial Highlights Reported revenues up 27.8% to GBP85.3 million (2007: GBP66.7 million); constant currency revenue growth of 14.3% Point-of-care (PoC) Division revenues up 37.4% to GBP34.3 million (2007:
Schering-Plough has received both the European Commission and the FDA approvals for the intravenous formulation of temozolomide as an alternative to the already approved oral form of the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.